$CUE
Cue Biopharma Inc

2023 Q2 Form 10-Q Financial Statement

#000095017023019646 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $1.382M $187.0K $1.000M
YoY Change 5215.38% -81.3% -35.61%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.249M $4.176M $5.156M
YoY Change 12.35% -19.01% 21.89%
% of Gross Profit
Research & Development $10.65M $9.391M $10.08M
YoY Change 11.03% -6.85% 2.71%
% of Gross Profit
Depreciation & Amortization $132.0K $174.0K $220.0K
YoY Change -37.74% -20.91% 0.92%
% of Gross Profit
Operating Expenses $14.90M $13.57M $15.24M
YoY Change 13.59% -10.97% 8.29%
Operating Profit -$13.52M -$13.38M -$14.24M
YoY Change 3.26% -6.03% 13.74%
Interest Expense $350.0K $330.4K $25.00K
YoY Change 69.9% 1221.67%
% of Operating Profit
Other Income/Expense, Net $332.0K $271.0K -$17.00K
YoY Change -381.36% -1694.12% -230.77%
Pretax Income -$13.19M -$13.11M -$14.26M
YoY Change -0.17% -8.04% 13.95%
Income Tax
% Of Pretax Income
Net Earnings -$13.19M -$13.11M -$14.26M
YoY Change -0.17% -8.04% 13.99%
Net Earnings / Revenue -954.05% -7010.16% -1425.5%
Basic Earnings Per Share -$0.29 -$0.29 -$0.44
Diluted Earnings Per Share -$0.29 -$0.29 -$436.8K
COMMON SHARES
Basic Shares Outstanding 43.18M 43.17M 33.01M
Diluted Shares Outstanding 44.80M 44.65M 32.64M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $57.89M $66.20M $67.93M
YoY Change -12.46% -2.54% -7.33%
Cash & Equivalents $52.90M $56.32M $67.93M
Short-Term Investments $4.988M $9.878M $0.00
Other Short-Term Assets $1.911M $2.360M $7.095M
YoY Change -10.78% -66.74% 162.78%
Inventory
Prepaid Expenses
Receivables $1.135M $196.0K $925.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $60.94M $68.76M $75.95M
YoY Change -11.69% -9.47% -1.88%
LONG-TERM ASSETS
Property, Plant & Equipment $1.192M $1.325M $1.918M
YoY Change -32.46% -30.92% -31.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $123.0K $125.0K $137.0K
YoY Change -8.21% -8.76% -95.28%
Total Long-Term Assets $12.23M $12.93M $14.76M
YoY Change -22.34% -12.4% 30.59%
TOTAL ASSETS
Total Short-Term Assets $60.94M $68.76M $75.95M
Total Long-Term Assets $12.23M $12.93M $14.76M
Total Assets $73.16M $81.68M $90.70M
YoY Change -13.67% -9.95% 2.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.356M $2.151M $2.617M
YoY Change 50.26% -17.81% 4.68%
Accrued Expenses $4.076M $2.843M $3.406M
YoY Change 14.53% -16.53% -51.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.000M $3.000M
YoY Change
Total Short-Term Liabilities $16.31M $13.81M $11.41M
YoY Change 95.93% 21.02% -31.26%
LONG-TERM LIABILITIES
Long-Term Debt $6.118M $7.077M $9.861M
YoY Change -38.28% -28.23%
Other Long-Term Liabilities $4.734M $5.778M $4.759M
YoY Change -29.94% 21.41% 98.29%
Total Long-Term Liabilities $6.118M $7.077M $9.861M
YoY Change -38.28% -28.23% 310.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.31M $13.81M $11.41M
Total Long-Term Liabilities $6.118M $7.077M $9.861M
Total Liabilities $27.16M $26.67M $26.03M
YoY Change 8.67% 2.44% 36.29%
SHAREHOLDERS EQUITY
Retained Earnings -$276.8M -$263.6M -$211.7M
YoY Change 23.05% 24.5%
Common Stock $322.8M $318.6M $276.4M
YoY Change 13.38% 15.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $46.00M $55.02M $64.67M
YoY Change
Total Liabilities & Shareholders Equity $73.16M $81.68M $90.70M
YoY Change -13.67% -9.95% 2.26%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$13.19M -$13.11M -$14.26M
YoY Change -0.17% -8.04% 13.99%
Depreciation, Depletion And Amortization $132.0K $174.0K $220.0K
YoY Change -37.74% -20.91% 0.92%
Cash From Operating Activities -$10.37M -$10.83M -$11.57M
YoY Change -19.28% -6.39% -1.88%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $27.00K
YoY Change -100.0% -100.0% -95.83%
Acquisitions
YoY Change
Other Investing Activities $5.000M $15.00M $0.00
YoY Change 166566.67% -100.0%
Cash From Investing Activities $5.000M $15.00M -$27.00K
YoY Change -8164.52% -55662.96% -100.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $191.0K
YoY Change 124.71%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.101M 388.0K 15.16M
YoY Change -81.09% -97.44% 1717.27%
NET CHANGE
Cash From Operating Activities -10.37M -10.83M -11.57M
Cash From Investing Activities 5.000M 15.00M -27.00K
Cash From Financing Activities 2.101M 388.0K 15.16M
Net Change In Cash -3.270M 4.557M 3.556M
YoY Change 81.57% 28.15% -321.01%
FREE CASH FLOW
Cash From Operating Activities -$10.37M -$10.83M -$11.57M
Capital Expenditures $0.00 $0.00 $27.00K
Free Cash Flow -$10.37M -$10.83M -$11.60M
YoY Change -18.87% -6.61% -6.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#LicenseMember
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001645460
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#LicenseMember
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#LicenseMember
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38327
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Cue Biopharma, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3324577
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
40 Guest Street
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
CY2023Q1 dei City Area Code
CityAreaCode
617
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
949-2680
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
CUE
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43178150
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56321000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51614000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
9878000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
24675000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
196000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
57000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2360000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
841000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
68755000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
77187000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1325000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1499000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8500000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9203000
CY2023Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2977000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
3116000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
125000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
128000
CY2023Q1 us-gaap Assets
Assets
81682000
CY2022Q4 us-gaap Assets
Assets
91283000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2151000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2731000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2843000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3554000
CY2023Q1 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
2521000
CY2022Q4 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
0
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3332000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3300000
CY2023Q1 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
2963000
CY2022Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
1963000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
13810000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11548000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5333000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6017000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7077000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8035000
CY2023Q1 cue Research And Development Contract Liability Net Of Current Portion
ResearchAndDevelopmentContractLiabilityNetOfCurrentPortion
445000
CY2022Q4 cue Research And Development Contract Liability Net Of Current Portion
ResearchAndDevelopmentContractLiabilityNetOfCurrentPortion
0
CY2023Q1 us-gaap Liabilities
Liabilities
26665000
CY2022Q4 us-gaap Liabilities
Liabilities
25600000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43178150
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43178150
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43042548
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43042548
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
43000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
43000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
318578000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
316192000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-39000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-96000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-263565000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-250456000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
55017000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
65683000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
81682000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91283000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
187000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1000000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4176000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5156000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9391000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10082000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
13567000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
15238000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13380000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14238000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
641000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8000
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-370000
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-25000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
271000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-13109000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14255000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
57000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13052000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14255000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44652353
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44652353
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32636383
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32636383
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65492000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10616000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3011000
CY2022Q1 cue Restricted Stock Awards Withheld At Vesting To Cover Taxes Amount
RestrictedStockAwardsWithheldAtVestingToCoverTaxesAmount
-191000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14255000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
64673000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
65683000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1998000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
388000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
57000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-13109000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
55017000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-13109000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-14255000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
177000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
303000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1998000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3011000
CY2023Q1 cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
703000
CY2022Q1 cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
-74000
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
2000
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-149000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3000
CY2023Q1 cue Accretion Of Final Payment On Term Loan
AccretionOfFinalPaymentOnTermLoan
33000
CY2022Q1 cue Accretion Of Final Payment On Term Loan
AccretionOfFinalPaymentOnTermLoan
0
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
139000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2218000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1518000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1093000
CY2023Q1 cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
139000
CY2022Q1 cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
53000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-580000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
26000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-709000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1215000
CY2023Q1 cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
2966000
CY2022Q1 cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-645000
CY2023Q1 cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-652000
CY2022Q1 cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
95000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10833000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11573000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
27000
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2023Q1 cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-15000000
CY2022Q1 cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-0
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15002000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27000
CY2023Q1 cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
0
CY2022Q1 cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
5489000
CY2023Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2022Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
388000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2023Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2022Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
142000
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
191000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
388000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15156000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4557000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3556000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51764000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
64521000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
56321000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68077000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
330000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
21000
CY2023Q1 cue Operating Lease Modification
OperatingLeaseModification
0
CY2022Q1 cue Operating Lease Modification
OperatingLeaseModification
1263000
CY2023Q1 cue Unsettled Cash Receivable From The Sale Of Common Stock
UnsettledCashReceivableFromTheSaleOfCommonStock
0
CY2022Q1 cue Unsettled Cash Receivable From The Sale Of Common Stock
UnsettledCashReceivableFromTheSaleOfCommonStock
5127000
CY2023Q1 us-gaap Marketable Securities
MarketableSecurities
66199000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.</span></p>
CY2023Q1 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P15Y
CY2023Q1 cue Pre Funded Warrants
PreFundedWarrants
1531440
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16233005
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7221051
CY2023Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
43861000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
9878000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
45423000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
24675000
CY2023Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
43861000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
9878000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
45423000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
24675000
CY2023Q1 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2022Q4 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
9878000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
24675000
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9917000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
39000
CY2023Q1 us-gaap Debt Securities Trading And Available For Sale
DebtSecuritiesTradingAndAvailableForSale
9878000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
24771000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
96000
CY2022Q4 us-gaap Debt Securities Trading And Available For Sale
DebtSecuritiesTradingAndAvailableForSale
24675000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
9878000
CY2023Q1 us-gaap Debt Securities Held To Maturity Threshold Period Past Due
DebtSecuritiesHeldToMaturityThresholdPeriodPastDue
P12M
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
39000
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
0
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5699000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5741000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4374000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4241000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1325000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1499000
CY2023Q1 us-gaap Depreciation
Depreciation
174000
CY2022Q1 us-gaap Depreciation
Depreciation
220000
CY2023Q1 cue Amortization Of Trademark
AmortizationOfTrademark
3000
CY2023Q1 cue Amortization Of Trademark
AmortizationOfTrademark
3000
CY2023Q1 cue Amortization Of Capitalized License Expense
AmortizationOfCapitalizedLicenseExpense
80000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2023Q1 cue Cash Obligation
CashObligation
20000000
CY2023Q1 us-gaap Interest Expense
InterestExpense
330417
CY2023Q1 us-gaap Interest Expense Other
InterestExpenseOther
32608
CY2022Q1 us-gaap Interest Expense Other
InterestExpenseOther
10869
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
7000000
CY2023Q1 cue Accretion Of Final Payment
AccretionOfFinalPayment
142000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-65000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7077000
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
3000000
CY2023Q1 us-gaap Deferred Finance Costs Current Gross
DeferredFinanceCostsCurrentGross
37000
CY2023Q1 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
2963000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2000000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4000000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4000000
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2023Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
141748
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0340
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0399
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.970
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.004
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0153
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0256
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.921
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.957
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6173867
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.60
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y18D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1321900
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.20
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
135602
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.86
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
315566
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.65
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7044599
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.66
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y11M15D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4364005
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.66
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y2M8D
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12835000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
18531000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
417000
CY2023Q1 cue Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare
9.66
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1998000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3011000
CY2023Q1 cue Number Of Tranches
NumberOfTranches
1
CY2023Q1 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2015-06-15
CY2023Q1 cue Pre Funded Warrants
PreFundedWarrants
1531440
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10719846
CY2023Q1 cue Class Of Warrants Or Rights Cashless Issue Exercises
ClassOfWarrantsOrRightsCashlessIssueExercises
0
CY2023Q1 cue Class Of Warrant Or Right Number Of Securities Withheld
ClassOfWarrantOrRightNumberOfSecuritiesWithheld
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
0
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10719846
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2500000
CY2020Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1250000
CY2021Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3000000
CY2023Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
146000
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
43000
CY2023Q1 us-gaap Security Deposit Liability
SecurityDepositLiability
595000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2494000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3368000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2799000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
818000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9479000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
814000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
8665000
CY2023Q1 cue Operating Leases Rent Expense
OperatingLeasesRentExpense
854000
CY2022Q1 cue Operating Leases Rent Expense
OperatingLeasesRentExpense
1338000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
652000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
95000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
145000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
145000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y14D
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y11M15D

Files In Submission

Name View Source Status
cue-20230331_def.xml Edgar Link unprocessable
0000950170-23-019646-index-headers.html Edgar Link pending
0000950170-23-019646-index.html Edgar Link pending
0000950170-23-019646.txt Edgar Link pending
0000950170-23-019646-xbrl.zip Edgar Link pending
cue-20230331.htm Edgar Link pending
cue-20230331.xsd Edgar Link pending
cue-ex10_1.htm Edgar Link pending
cue-ex10_2.htm Edgar Link pending
cue-ex31_1.htm Edgar Link pending
cue-ex31_2.htm Edgar Link pending
cue-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img77021050_0.jpg Edgar Link pending
img77021050_1.jpg Edgar Link pending
img77021050_2.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
cue-20230331_cal.xml Edgar Link unprocessable
cue-20230331_lab.xml Edgar Link unprocessable
cue-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cue-20230331_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending